76.90
-0.63 (-0.81%)
| Previous Close | 77.53 |
| Open | 77.04 |
| Volume | 1,073,964 |
| Avg. Volume (3M) | 2,211,232 |
| Market Cap | 8,994,685,952 |
| Price / Earnings (TTM) | 17.60 |
| Price / Earnings (Forward) | 8.19 |
| Price / Sales | 7.76 |
| Price / Book | 25.20 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 44.76% |
| Operating Margin (TTM) | 53.44% |
| Diluted EPS (TTM) | 3.76 |
| Quarterly Revenue Growth (YOY) | 35.20% |
| Quarterly Earnings Growth (YOY) | 53.70% |
| Total Debt/Equity (MRQ) | 318.67% |
| Current Ratio (MRQ) | 8.39 |
| Operating Cash Flow (TTM) | 503.86 M |
| Levered Free Cash Flow (TTM) | 402.43 M |
| Return on Assets (TTM) | 18.50% |
| Return on Equity (TTM) | 147.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Halozyme Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 101.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (HC Wainwright & Co., 17.04%) | Buy |
| 90.00 (Benchmark, 17.04%) | Buy | |
| Median | 78.50 (2.08%) | |
| Low | 63.00 (JP Morgan, -18.08%) | Hold |
| Average | 78.33 (1.86%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 66.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 20 Oct 2025 | 79.00 (2.73%) | Buy | 66.47 |
| 18 Aug 2025 | 80.00 (4.03%) | Buy | 68.96 | |
| HC Wainwright & Co. | 15 Oct 2025 | 90.00 (17.04%) | Buy | 66.36 |
| 02 Oct 2025 | 90.00 (17.04%) | Buy | 71.69 | |
| Leerink Partners | 14 Oct 2025 | 70.00 (-8.97%) | Hold | 66.65 |
| Benchmark | 24 Sep 2025 | 90.00 (17.04%) | Buy | 75.64 |
| JP Morgan | 07 Aug 2025 | 63.00 (-18.08%) | Hold | 62.10 |
| JMP Securities | 06 Aug 2025 | 78.00 (1.43%) | Buy | 62.32 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Oct 2025 | Announcement | Halozyme to Report Third Quarter 2025 Financial and Operating Results |
| 01 Oct 2025 | Announcement | Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s |
| 28 Aug 2025 | Announcement | Halozyme to Participate at Upcoming Investor Conferences |
| 05 Aug 2025 | Announcement | HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |